Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization. [electronic resource]
Producer: 20200921Description: 92-100 p. digitalISSN:- 1942-7611
- Angiogenesis Inhibitors -- blood
- Animals
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Endothelial Cells -- cytology
- Female
- Half-Life
- Human Umbilical Vein Endothelial Cells
- Humans
- Mice, Inbred C57BL
- Neovascularization, Pathologic -- drug therapy
- Neovascularization, Physiologic -- drug effects
- Single-Domain Antibodies -- blood
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.